Lansen Pharmaceutical Holdings Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lansen Pharmaceutical Holdings Limited with three other
companies in this sector in CHINA :
Fujian Cosunter Pharmaceutical Co Ltd
sales of 414.86 million Chinese Renmimbi [US$61.26 million]
of which 100%
Jiangxi Synergy Pharmaceutical Co Ltd
(413.06 million Chinese Renmimbi [US$61.00 million]
of which 100%
was Pharmaceutical manufacture), and
Wuhan Hvsen Biotechnology Co Ltd
(427.22 million Chinese Renmimbi [US$63.09 million]
of which 26%
was Acetylisovaleryltylosin Tartrate).
During the year ended December of 2019, sales at
Lansen Pharmaceutical Holdings Limited were 428.60 million Chinese Renmimbi (US$63.29 million).
increase of 13.8%
versus 2018, when the company's sales were 376.56 million Chinese Renmimbi.
Despite this increase, sales are still
below the level achieved in 2017, when Lansen Pharmaceutical Holdings Limited
reported sales of 602.67 million Chinese Renmimbi.
Sales of Specialty Pharmaceuticals saw an increase
9.6% in 2019, from
318.18 million Chinese Renmimbi to 348.68 million Chinese Renmimbi.
Not all segments of Lansen Pharmaceutical Holdings Limited experienced an increase in sales in 2019:
sales of Medical Cosmetics Produts fell 91.8% to 1.28 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Lansen Pharmaceutical Holdings Limited also experienced decreases in sales in
Healthcare Products (down 43.1% to 24.39 million Chinese Renmimbi)